{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:21:41Z","timestamp":1772166101982,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Department of Cardiology, Isala Hospital, Zwolle"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several studies compared everolimus-eluting bioresorbable scaffolds (EE-BRS) with everolimus-eluting stents (EES), but only few assessed these devices in patients with diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy outcomes of all-comer patients with diabetes mellitus\u00a0up to 2\u00a0years after treatment with EE-BRS or EES.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a post hoc pooled analysis of patient-level data in diabetic patients who were treated with EE-BRS or EES in 3 prospective clinical trials: The ABSORB DM Benelux Study (NTR5447), TWENTE (NTR1256\/NCT01066650) and DUTCH PEERS (NTR2413\/NCT01331707). Primary endpoint of the analysis was target lesion failure (TLF): a composite of cardiac death, target vessel myocardial infarction or clinically driven target lesion revascularization. Secondary endpoints included major adverse cardiac events (MACE): a composite of all-cause death, any myocardial infarction or clinically driven target vessel revascularization, as well as definite or probable device thrombosis (ST).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 499 diabetic patients were assessed, of whom 150 received EE-BRS and 249 received EES. Total available follow-up was 222.6 patient years (PY) in\u00a0the EE-BRS and 464.9 PY in the\u00a0EES\u00a0group. The adverse events rates were similar in both treatment groups for TLF (7.2 vs. 5.2 events per 100 PY, p\u2009=\u20090.39; adjusted hazard ratio (HR)\u2009=\u20091.48 (95% confidence interval (CI): 0.77\u20132.87), p\u2009=\u20090.24), MACE (9.1 vs. 8.3 per 100 PY, p\u2009=\u20090.83; adjusted HR\u2009=\u20091.23 (95% CI: 0.70\u20132.17), p\u2009=\u20090.47), and ST (0.9 vs. 0.6 per 100 PY, p\u2009&gt;\u20090.99).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this patient-level pooled analysis of patients with diabetes mellitus from 3 clinical trials, EE-BRS showed clinical outcomes that were quite similar to EES.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-020-01116-2","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T06:02:58Z","timestamp":1601618578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Everolimus-eluting bioresorbable scaffolds and metallic stents in diabetic patients: a patient-level pooled analysis of the prospective ABSORB DM Benelux Study, TWENTE and DUTCH PEERS"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-6254","authenticated-orcid":false,"given":"T. M.","family":"Hommels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. S.","family":"Hermanides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Berta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. H.","family":"Ploumen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"von Birgelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kedhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"key":"1116_CR1","doi-asserted-by":"publisher","first-page":"e002328","DOI":"10.1161\/CIRCINTERVENTIONS.114.002328","volume":"8","author":"V Ritsinger","year":"2015","unstructured":"Ritsinger V, Saleh N, Lagerqvist B, Norhammer A. High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish coronary angiography and angioplasty registry. Circ Cardiovasc Interv. 2015;8:e002328.","journal-title":"Circ Cardiovasc Interv"},{"key":"1116_CR2","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1161\/01.CIR.0000131898.18849.65","volume":"109","author":"M Singh","year":"2004","unstructured":"Singh M, Gersh BJ, McClelland RL, et al. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the prevention of restenosis with tranilast and its outcomes (PRESTO) trial. Circulation. 2004;109:2727\u201331.","journal-title":"Circulation"},{"key":"1116_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0735-1097(02)01971-X","volume":"40","author":"E Van Belle","year":"2002","unstructured":"Van Belle E, P\u00e9ri\u00e9 M, Braune D, et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol. 2002;40:410\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"1116_CR4","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ahj.2012.02.006","volume":"163","author":"E Grube","year":"2012","unstructured":"Grube E, Chevalier B, Guagliumi G, et al. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Libert\u00e9 paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am Heart J. 2012;163:867\u201375.","journal-title":"Am Heart J"},{"key":"1116_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.amjcard.2011.10.018","volume":"109","author":"LO Jensen","year":"2012","unstructured":"Jensen LO, Maeng M, Thayssen P, et al. Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2012;109:629\u201335.","journal-title":"Am J Cardiol"},{"key":"1116_CR6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1161\/CIRCULATIONAHA.111.031070","volume":"124","author":"GW Stone","year":"2011","unstructured":"Stone GW, Kedhi E, Kereiakes DJ, et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation. 2011;124:893\u2013900.","journal-title":"Circulation"},{"key":"1116_CR7","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2004.07.060","volume":"44","author":"PR Moreno","year":"2004","unstructured":"Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol. 2004;44:2293\u2013300.","journal-title":"J Am Coll Cardiol"},{"key":"1116_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1161\/CIRCINTERVENTIONS.110.958249","volume":"3","author":"K Yamaji","year":"2010","unstructured":"Yamaji K, Kimura T, Morimoto T, et al. Very long-term (15 to 20\u00a0years) clinical and angiographic outcome after coronary bare metal stent implantation. Circ Cardiovasc Interv. 2010;3:468\u201375.","journal-title":"Circ Cardiovasc Interv"},{"key":"1116_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.113.001790","volume":"129","author":"F Otsaka","year":"2014","unstructured":"Otsaka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129:211\u201323.","journal-title":"Circulation"},{"key":"1116_CR10","first-page":"e002230","volume":"8","author":"J Iqbal","year":"2015","unstructured":"Iqbal J, Serruys PW, Silber S, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8:e002230.","journal-title":"Circ Cardiovasc Interv"},{"key":"1116_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1161\/CIRCULATIONAHA.116.021539","volume":"134","author":"DJ Kereiakes","year":"2016","unstructured":"Kereiakes DJ, Onuma Y, Serruys PW, Stone GW. Bioresorbable vascular scaffolds for coronary revascularization. Circulation. 2016;134:168\u201382.","journal-title":"Circulation"},{"key":"1116_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12872-016-0207-5","volume":"16","author":"E Tenekecioglu","year":"2016","unstructured":"Tenekecioglu E, Farooq V, Bourantes CV, et al. Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. BMC Cardiovasc Disord. 2016;16:38.","journal-title":"BMC Cardiovasc Disord"},{"key":"1116_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s12471-019-1293-7","volume":"27","author":"TM Hommels","year":"2019","unstructured":"Hommels TM, Hermanides RS, Rasoul S, et al. The 1-year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study. Neth Heart J. 2019;27:541\u20139.","journal-title":"Neth Heart J"},{"key":"1116_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12933-019-0827-z","volume":"18","author":"TM Hommels","year":"2019","unstructured":"Hommels TM, Hermanides RS, Rasoul S, et al. Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study. Cardiovasc Diabetol. 2019;18:25.","journal-title":"Cardiovasc Diabetol"},{"key":"1116_CR15","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.jacc.2012.01.008","volume":"59","author":"C von Birgelen","year":"2012","unstructured":"von Birgelen C, Basalus MW, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol. 2012;59:1350\u201361.","journal-title":"J Am Coll Cardiol"},{"key":"1116_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(13)62037-1","volume":"383","author":"C von Birgelen","year":"2014","unstructured":"von Birgelen C, Sen H, Lam MK, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383:413\u201323.","journal-title":"Lancet"},{"key":"1116_CR17","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344\u201351.","journal-title":"Circulation"},{"key":"1116_CR18","first-page":"871","volume":"5","author":"P Vranckx","year":"2010","unstructured":"Vranckx P, Cutlip DE, Mehran R, et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity Addendum to the historical MI definitions used in stent studies. Euro Intervention. 2010;5:871\u20134.","journal-title":"Euro Intervention"},{"key":"1116_CR19","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","volume":"60","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581\u201398.","journal-title":"J Am Coll Cardiol"},{"key":"1116_CR20","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s12350-015-0209-1","volume":"22","author":"KA Hicks","year":"2015","unstructured":"Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards). J Nucl Cardiol. 2015;22:1041\u20134.","journal-title":"J Nucl Cardiol"},{"key":"1116_CR21","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/j.jcin.2018.09.033","volume":"11","author":"M Konigstein","year":"2018","unstructured":"Konigstein M, Ben-Yehuda O, Smits PC, et al. Outcomes among diabetic patients undergoing percutaneous coronary intervention with contemporary drug-eluting stents: analysis from the BIONICS randomized trial. JACC Cardiovasc Interv. 2018;11:2467\u201376.","journal-title":"JACC Cardiovasc Interv"},{"key":"1116_CR22","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.jacc.2019.01.037","volume":"73","author":"M Milojevic","year":"2019","unstructured":"Milojevic M, Serruys PW, Sabik JF 3rd, et al. Bypass surgery or stenting for left main coronary artery disease in patients with diabetes. J Am Coll Cardiol. 2019;73:1616\u201328.","journal-title":"J Am Coll Cardiol"},{"key":"1116_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jjcc.2019.07.016","volume":"75","author":"A Konishi","year":"2020","unstructured":"Konishi A, Mitsutake Y, Ho M, et al. Patient and lesion characteristics in late\/very late stent thrombosis with everolimus-eluting stents from real-world adverse event reporting. J Cardiol. 2020;75:255\u201360.","journal-title":"J Cardiol"},{"key":"1116_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jcin.2016.10.019","volume":"10","author":"DJ Kereiakes","year":"2017","unstructured":"Kereiakes DJ, Ellis SG, Kimura T, et al. Efficacy\u00a0and\u00a0safety\u00a0of the Absorb everolimus-eluting bioresorbable scaffold for treatment of patients with diabetes mellitus: results of the\u00a0Absorb\u00a0diabetic substudy. JACC Cardiovasc Interv. 2017;10:42\u20139.","journal-title":"JACC Cardiovasc Interv"},{"key":"1116_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12933-018-0758-0","volume":"17","author":"XF Tang","year":"2018","unstructured":"Tang XF, Ma YL, Song Y, et al. Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study. Cardiovasc Diabetol. 2018;17:114.","journal-title":"Cardiovasc Diabetol"},{"key":"1116_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/ccd.27109","volume":"91","author":"CM Campos","year":"2018","unstructured":"Campos CM, Caixeta A, Franken M, et al. Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials. Catheter Cardiovasc Interv. 2018;91:387\u201395.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1116_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12872-018-0811-7","volume":"18","author":"R Anadol","year":"2018","unstructured":"Anadol R, Schnitzler K, Lorenz L, et al. Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds. BMC Cardiovasc Disord. 2018;18:92.","journal-title":"BMC Cardiovasc Disord"},{"key":"1116_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0140-6736(14)61455-0","volume":"385","author":"PW Serruys","year":"2015","unstructured":"Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43\u201354.","journal-title":"Lancet"},{"key":"1116_CR29","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","volume":"373","author":"SG Ellis","year":"2015","unstructured":"Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905\u201315.","journal-title":"N Engl J Med"},{"key":"1116_CR30","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1016\/j.jacc.2017.10.010","volume":"70","author":"DJ Kereiakes","year":"2017","unstructured":"Kereiakes DJ, Ellis SG, Metzger C, et al. 3-Year clinical outcomes with\u00a0everolimus-eluting bioresorbable\u00a0coronary scaffolds: the\u00a0ABSORB III trial. J Am Coll Cardiol. 2017;70:2852\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"1116_CR31","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","volume":"388","author":"PW Serruys","year":"2016","unstructured":"Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3\u00a0year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388:2479\u201391.","journal-title":"Lancet"},{"key":"1116_CR32","first-page":"e426","volume":"14","author":"RYG Tijssen","year":"2018","unstructured":"Tijssen RYG, Kraak RP, Hofma SH, et al. Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI. Euro Intervention. 2018;14:e426\u201333.","journal-title":"Euro Intervention"},{"key":"1116_CR33","first-page":"2110","volume":"12","author":"L Ortega-Paz","year":"2017","unstructured":"Ortega-Paz L, Capodanno D, Gori T, et al. Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. Euro Intervention. 2017;12:2110\u20137.","journal-title":"Euro Intervention"},{"key":"1116_CR34","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1016\/j.jacc.2017.09.1106","volume":"70","author":"GW Stone","year":"2017","unstructured":"Stone GW, Abizaid A, Onuma Y, et al. Effect of technique on outcomes following bioresorbable vascular scaffold implantation: analysis from the ABSORB trials. J Am Coll Cardiol. 2017;70:2863\u201374.","journal-title":"J Am Coll Cardiol"},{"key":"1116_CR35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.4244\/EIJ-D-16-00796","volume":"15","author":"A Caixeta","year":"2019","unstructured":"Caixeta A, Campos CM, Felix C, et al. Predictors of long-term adverse events after Absorb bioresorbable vascular scaffold implantation: a 1,933-patient pooled analysis from international registries. EuroIntervention. 2019;15:623\u201330.","journal-title":"EuroIntervention."},{"key":"1116_CR36","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.4244\/EIJ-D-17-00873","volume":"13","author":"B Chevalier","year":"2018","unstructured":"Chevalier B, Cequier A, Dudek D, et al. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II trial). EuroIntervention. 2018;13:1561\u20134.","journal-title":"EuroIntervention."},{"key":"1116_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ccd.28290","volume":"95","author":"S Goel","year":"2020","unstructured":"Goel S, Pasam RT, Chava S, et al. Three to four years outcomes of the Absorb bioresorbable vascular scaffold versus second-generation drug-eluting stent: a meta-analysis. Catheter Cardiovasc Interv. 2020;95:216\u201323.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1116_CR38","doi-asserted-by":"publisher","first-page":"607","DOI":"10.4244\/EIJ-D-19-00324","volume":"15","author":"A Seth","year":"2019","unstructured":"Seth A, Onuma Y, Chandra P, et al. Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial. EuroIntervention. 2019;15:607\u201314.","journal-title":"EuroIntervention"},{"key":"1116_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12933-019-0819-z","volume":"18","author":"Z Qin","year":"2019","unstructured":"Qin Z, Zhou K, Li YP, et al. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study. Cardiovasc Diabetol. 2019;18:11.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01116-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-020-01116-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01116-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T20:08:27Z","timestamp":1633118907000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01116-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1116"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01116-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-37481\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-37481\/v2","asserted-by":"object"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,2]]},"assertion":[{"value":"28 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ABSORB DM Benelux Study (NTR5447) was performed in concurrence with the Declaration of Helsinki and was registered at the Netherlands Trial Register (NTR) acknowledged by the World Health Organization (WHO) and International Committee of Medical Journal Editors (ICMJE). The TWENTE (NTR1256\/NCT01066650) and DUTCH PEERS (NTR2413\/NCT01331707) trials were both conducted in concurrence with the Declaration of Helsinki and were registered at the NTR as well as at ClinicalTrials.gov. An approval for ethical committees was sought in all participating centers and countries. The clinical investigations did not test any non-approved device. The ABSORB BVS and the ABSORB GT1 are CE marked products and were used widely in daily clinical practice all over the world from 2009 to 2017. The Xience V EES is widely utilized since 2007 and the Promus Element EES since 2010. These clinical trials do not involve a medicinal product and are therefore not subject to The European Clinical Trials Directive (2001\/20\/EC).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E.H. Ploumen and C. von Birgelen indicated that the research department of Thoraxcentrum Twente has received institutional research grants from Abbott Vascular, Biotronik, Boston Scientific and Medtronic. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}